All Funds
| Company | Time in Market | Invested | Valuation at Entry | Current / Exit Value | Shares | Status | Source |
|---|---|---|---|---|---|---|---|
Hadean Capital I as Fund Vehicle / Holding · Norway | 10.3 yr Direct · 2017 | Undisclosed | Undisclosed | Undisclosed | 192 650 (1.95%) | Active | — |
CardioMech MedTech / Cardiology · Norway | 7.3 yr Series A · 2020 | NOK 40M | NOK 150M | NOK 400M | 4 591 019 Preference (3.47%) | Active | — |
Hadean F2 Investco as Real Estate · Norway | 7.3 yr Direct · 2020 | Undisclosed | Undisclosed | Undisclosed | 68 500 (68.50%) | Active | — |
Alex Therapeutics Digital Therapeutics · Sweden | 5.9 yr Seed · 2020 | Undisclosed | Undisclosed | Undisclosed | — | Active | — |
Actithera Radiopharmaceuticals · Norway | 6.3 yr Seed · 2021 | Undisclosed | Undisclosed | Undisclosed | — | Active | — |
Neuro Event Labs Digital Health / Neurology · Finland | 6.3 yr Seed · 2021 | Undisclosed | Undisclosed | Undisclosed | — | Active | — |
Hadean Capital Ii as Fund Vehicle / Holding · Norway | 6.3 yr Direct · 2021 | Undisclosed | Undisclosed | Undisclosed | 2 362 246 (2.00%) | Active | — |
Emergence Therapeutics Biopharmaceuticals / Oncology · Germany | 5.1 yr Series A · 2021 | Undisclosed | Undisclosed | Undisclosed | — | Active | — |
Cardior Biopharmaceuticals / Cardiology · Germany | 4.9 yr Series A · 2021 | NOK 55M | NOK 220M | NOK 500M | — | Active | — |
SAGA Diagnostics MedTech / Liquid Biopsy · Sweden | 4.9 yr Series A · 2021 | Undisclosed | Undisclosed | Undisclosed | — | Active | — |
Attgeno Pharma / Gene Editing · Sweden | 4.7 yr Seed · 2021 | Undisclosed | Undisclosed | Undisclosed | — | Active | — |
Complement Therapeutics Biotechnology · Germany | 5.3 yr Seed · 2022 | Undisclosed | Undisclosed | Undisclosed | — | Active | — |
Step Pharma Therapeutics / Immunology · Switzerland | 5.3 yr Series A · 2022 | Undisclosed | Undisclosed | Undisclosed | — | Active | — |
Arthex Biotech RNA Therapeutics · Spain | 4.2 yr Seed · 2022 | Undisclosed | Undisclosed | Undisclosed | — | Active | — |
SciRhom Biotech / Inflammation · Germany | 3.9 yr Series A · 2022 | Undisclosed | Undisclosed | Undisclosed | — | Active | — |
Contineum Therapeutics Therapeutics / CNS · USA | 3.7 yr Series A · 2022 | Undisclosed | Undisclosed | Undisclosed | — | Active | — |
TargED Biopharmaceuticals Biopharmaceuticals / Oncology · Norway | 4.3 yr Seed · 2023 | Undisclosed | Undisclosed | Undisclosed | — | Active | — |
Ribbon Bio Biotech / DNA Synthesis · USA | 3.2 yr Seed · 2023 | Undisclosed | Undisclosed | Undisclosed | — | Active | — |
Hadean Growth Fund I as Fund Vehicle / Holding · Norway | 3.3 yr Direct · 2024 | Undisclosed | Undisclosed | Undisclosed | 300 000 (100.00%) | Active | — |
Showing 19 investments · Valuations are estimates based on public data and last known rounds